Developer docs
API playgroundTry for free, no card

Search company profiles

Micreos Group

Full company profile

uuid003pvst

Namestring
Micreos Group
Company typeenum
Private
Founded yearint
2005
Descriptiontext

Micreos Group is a privately held Dutch biotechnology company headquartered in Bilthoven, Netherlands, founded in 2005. The company develops endolysin and bacteriophage-based solutions targeting two distinct application verticals: skin health, commercialized through its Gladskin consumer brand, and food safety, commercialized through its PhageGuard brand. The underlying technology leverages naturally occurring phage-derived enzymes (endolysins) and intact bacteriophages as targeted antimicrobial agents, offering an alternative to conventional antibiotics and chemical preservatives.

The company operates with 51-100 employees and maintains a private, for-profit corporate structure. No further firmographic detail — including funding history, ownership, customer base, pricing, geographic footprint, management roster, or revenue — is available in the supplied data, as the company's website scraping was blocked by a verification/loading page. This represents a significant data gap for deeper due diligence.

Micreos' business model appears to combine a direct-to-consumer motion (Gladskin skincare products targeting consumers with skin conditions such as eczema and acne) with a B2B ingredient or licensing motion (PhageGuard applications for food producers seeking biopreservative alternatives). However, without disclosed revenue mechanics, customer counts, or pricing structures, the relative weighting of these channels and overall revenue scale cannot be assessed from the available information.

Short descriptiontext

Micreos Group is a Dutch biotech company, founded in 2005, that develops proprietary endolysin and bacteriophage-based antimicrobial solutions for skin health (Gladskin) and food safety (PhageGuard) applications.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersBilthoven, Netherlands
HQ citystring
Bilthoven
HQ countrystring
Netherlands
HQ regionstring
Europe
Markets served

Serves global market

Keyword5 values
bacteriophage technology, endolysin therapeutics, food safety bioprotection, skin microbiome products, antimicrobial biotechnology
Industry5 codes
PRIMARYAFAJAFAF
Natural Antimicrobials & Clean-Label Preservatives (Plant Extracts, Essential Oils, Fermented Extracts)
Agriculture & Food Production/Food Ingredients & Additives/Preservatives & Antimicrobials (Organic Acids, Nitrates, Cultured Dextrose)
SECONDARYAFAJAJAF
Protective Cultures & Biopreservation (Anti-Listeria, Anti-Mold, Shelf-Life Cultures)
Agriculture & Food Production/Food Ingredients & Additives/Cultures & Fermentation Ingredients (Starter Cultures, Probiotics, Yeast)
SECONDARYCRADAOAF
Preservatives & Antimicrobials (Sorbates, Benzoates, Natamycin, Cultured Dextrose)
SECONDARYCRADANAI
Hand Sanitizers & Antibacterial Personal Care
Consumer Products & Retail/Consumer Packaged Goods (CPG) Manufacturing & Brands/Consumer Fragrances & Personal Care Manufacturing (Non-cosmetic)
SECONDARYCRABAEAH
Antibacterial & Medicated Cleansers (e.g., Acne, Antifungal, Antiseptic)
Consumer Products & Retail/Beauty & Personal Care/Bath, Body & Personal Cleansing
NAICS code1 code
  • Pharmaceutical Preparation Manufacturing325412
SIC code2 codes
  • Food And Kindred Products2000
  • Perfumes, Cosmetics & Other Toilet Preparations2844
Product category
Antimicrobial Biotechnology
Social media profiles1 record
Cost components5 values
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales
GTM typeB2B and B2C
B2B and B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Micreos Group develops and commercializes endolysin- and bacteriophage-based antibacterial solutions. Its consumer-facing Gladskin brand offers microbiome-friendly skincare products for conditions such as eczema, acne, rosacea and sensitive skin, while its PhageGuard brand provides food-safety bioprotection products used by meat, poultry and other food producers to control specific pathogenic bacteria such as Salmonella and Listeria.

Differentiator
Functional benefit
Problem solved
Product and service1 record
1Gladskin
Expansion highlight1 record

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

SkinBioTherapeutics develops microbiome-based skincare ingredients and consumer products, paralleling Micreos's Gladskin line in applying biological science to skin health.

TypeEmerging player
Description

Eligo Bioscience develops phage-based and microbiome-engineering platforms for therapeutic and consumer applications, sharing Micreos's core bacteriophage technology foundation.

3BioGaia
TypeBroad incumbent
Description

BioGaia is an established probiotic health-products company whose probiotic formulations for skin and consumer health overlap thematically with Gladskin's microbiome-based skin positioning.

TypeDirect peer
Description

Intralytix develops and commercializes phage-based products for food safety, directly overlapping Micreos's PhageGuard portfolio and serving similar food-processing customers with bacteriophage antimicrobial solutions.

TypeBroad incumbent
Description

IFF is a global food ingredients and biosciences major whose Health & Biosciences division includes antimicrobials, cultures, and food protection solutions that overlap with PhageGuard's food safety applications.

TypeBroad incumbent
Description

Novonesis is a global bioscience leader offering food cultures, enzymes, and bioprotection solutions; its bioprotective cultures overlap with Micreos's clean-label food preservation positioning at much larger scale.

TypeEmerging player
Description

Locus FS produces biological fermentation-derived ingredients, including clean-label antimicrobials and shelf-life solutions that compete with Micreos's PhageGuard in natural food preservation.

TypeEmerging player
Description

AOBiome develops live bacterial and microbiome-based therapeutics for skin conditions, sharing Gladskin's biological approach to skin health with a more clinical/therapeutic orientation.

9DuPont Nutrition & Biosciences (IFF Danisco)
TypeBroad incumbent
Description

DuPont's cultures and preservatives portfolio (now part of IFF) competes directly with PhageGuard in supplying antimicrobial and shelf-life extension solutions to food manufacturers.

10Phagelux
TypeDirect peer
Description

Phagelux applies phage technology to food safety and agricultural applications, competing head-to-head with PhageGuard in biological antimicrobials for the food industry.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat2 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Micreos Group

Antimicrobial Biotechnologymicreos-group.com

Micreos Group is a Dutch biotech company, founded in 2005, that develops proprietary endolysin and bacteriophage-based antimicrobial solutions for skin health (Gladskin) and food safety (PhageGuard) applications.

What Micreos Group does

Micreos Group is a privately held Dutch biotechnology company headquartered in Bilthoven, Netherlands, founded in 2005. The company develops endolysin and bacteriophage-based solutions targeting two distinct application verticals: skin health, commercialized through its Gladskin consumer brand, and food safety, commercialized through its PhageGuard brand. The underlying technology leverages naturally occurring phage-derived enzymes (endolysins) and intact bacteriophages as targeted antimicrobial agents, offering an alternative to conventional antibiotics and chemical preservatives.

The company operates with 51-100 employees and maintains a private, for-profit corporate structure. No further firmographic detail — including funding history, ownership, customer base, pricing, geographic footprint, management roster, or revenue — is available in the supplied data, as the company's website scraping was blocked by a verification/loading page. This represents a significant data gap for deeper due diligence.

Micreos' business model appears to combine a direct-to-consumer motion (Gladskin skincare products targeting consumers with skin conditions such as eczema and acne) with a B2B ingredient or licensing motion (PhageGuard applications for food producers seeking biopreservative alternatives). However, without disclosed revenue mechanics, customer counts, or pricing structures, the relative weighting of these channels and overall revenue scale cannot be assessed from the available information.

Micreos Group firmographics

Firmographics
Name
Micreos Group
Website
https://micreos-group.com
Company type
Private
Founded year
2005
Operating status
Operating
Headcount range
51–100 employees
Short description
Micreos Group is a Dutch biotech company, founded in 2005, that develops proprietary endolysin and bacteriophage-based antimicrobial solutions for skin health (Gladskin) and food safety (PhageGuard) applications.
Ownership category
akta.pro rank

Micreos Group industry classification

Industry
Product category
Antimicrobial Biotechnology
NAICS
Pharmaceutical Preparation Manufacturing (325412)
SIC
Food And Kindred Products (2000), Perfumes, Cosmetics & Other Toilet Preparations (2844)
akta.pro industry
PRIMARYAFAJAFAF
Natural Antimicrobials & Clean-Label Preservatives (Plant Extracts, Essential Oils, Fermented Extracts)
Agriculture & Food Production/Food Ingredients & Additives/Preservatives & Antimicrobials (Organic Acids, Nitrates, Cultured Dextrose)
SECONDARYAFAJAJAF
Protective Cultures & Biopreservation (Anti-Listeria, Anti-Mold, Shelf-Life Cultures)
Agriculture & Food Production/Food Ingredients & Additives/Cultures & Fermentation Ingredients (Starter Cultures, Probiotics, Yeast)
SECONDARYCRADAOAF
Preservatives & Antimicrobials (Sorbates, Benzoates, Natamycin, Cultured Dextrose)
SECONDARYCRADANAI
Hand Sanitizers & Antibacterial Personal Care
Consumer Products & Retail/Consumer Packaged Goods (CPG) Manufacturing & Brands/Consumer Fragrances & Personal Care Manufacturing (Non-cosmetic)
SECONDARYCRABAEAH
Antibacterial & Medicated Cleansers (e.g., Acne, Antifungal, Antiseptic)
Consumer Products & Retail/Beauty & Personal Care/Bath, Body & Personal Cleansing

Keywords

  • Bacteriophage technology
  • Endolysin therapeutics
  • Food safety bioprotection
  • Skin microbiome products
  • Antimicrobial biotechnology

Where Micreos Group is headquartered

Location

Headquarters

HQ city
Bilthoven
HQ country
Netherlands
HQ region
Europe

Markets served

Micreos Group business model

Business model
GTM type
B2B and B2C
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales

Micreos Group product offering

Product offering

Core offering

Micreos Group develops and commercializes endolysin- and bacteriophage-based antibacterial solutions. Its consumer-facing Gladskin brand offers microbiome-friendly skincare products for conditions such as eczema, acne, rosacea and sensitive skin, while its PhageGuard brand provides food-safety bioprotection products used by meat, poultry and other food producers to control specific pathogenic bacteria such as Salmonella and Listeria.

Differentiator

Problem solved

Functional benefit

Products and services

  • Gladskin

Companies that use Micreos Group

Customer profile

Ideal customer profiles2 records

Micreos Group technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Micreos Group partnerships and signals

Strategic signal

Expansion highlights1 record

Micreos Group competitors and assessment

Company assessment

Emerging players

  • SkinBioTherapeutics: SkinBioTherapeutics develops microbiome-based skincare ingredients and consumer products, paralleling Micreos's Gladskin line in applying biological science to skin health.
  • Eligo Bioscience: Eligo Bioscience develops phage-based and microbiome-engineering platforms for therapeutic and consumer applications, sharing Micreos's core bacteriophage technology foundation.
  • Locus Fermentation Solutions: Locus FS produces biological fermentation-derived ingredients, including clean-label antimicrobials and shelf-life solutions that compete with Micreos's PhageGuard in natural food preservation.
  • AOBiome: AOBiome develops live bacterial and microbiome-based therapeutics for skin conditions, sharing Gladskin's biological approach to skin health with a more clinical/therapeutic orientation.

Broad incumbents

  • BioGaia: BioGaia is an established probiotic health-products company whose probiotic formulations for skin and consumer health overlap thematically with Gladskin's microbiome-based skin positioning.
  • International Flavors & Fragrances (IFF): IFF is a global food ingredients and biosciences major whose Health & Biosciences division includes antimicrobials, cultures, and food protection solutions that overlap with PhageGuard's food safety applications.
  • Novonesis (formerly Novozymes / Chr. Hansen): Novonesis is a global bioscience leader offering food cultures, enzymes, and bioprotection solutions; its bioprotective cultures overlap with Micreos's clean-label food preservation positioning at much larger scale.
  • DuPont Nutrition & Biosciences (IFF Danisco): DuPont's cultures and preservatives portfolio (now part of IFF) competes directly with PhageGuard in supplying antimicrobial and shelf-life extension solutions to food manufacturers.

Direct peers

  • Intralytix: Intralytix develops and commercializes phage-based products for food safety, directly overlapping Micreos's PhageGuard portfolio and serving similar food-processing customers with bacteriophage antimicrobial solutions.
  • Phagelux: Phagelux applies phage technology to food safety and agricultural applications, competing head-to-head with PhageGuard in biological antimicrobials for the food industry.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat2 records

Key risks5 records

Key highlights5 records

Customer concentration

Micreos Group social profiles

Digital presence

Micreos Group financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Micreos Group leadership team

Management profile

Number of profiles

Micreos Group funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Micreos Group M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Micreos Group

What does Micreos Group do?

Micreos Group develops and commercializes endolysin- and bacteriophage-based antibacterial solutions. Its consumer-facing Gladskin brand offers microbiome-friendly skincare products for conditions such as eczema, acne, rosacea and sensitive skin, while its PhageGuard brand provides food-safety bioprotection products used by meat, poultry and other food producers to control specific pathogenic bacteria such as Salmonella and Listeria.

Is Micreos Group a public or private company?

Micreos Group is a private company. It is classified as venture growth investor backed and is currently operating.

When was Micreos Group founded?

Micreos Group was founded in 2005. It employs 51 to 100 people.

Where is Micreos Group based?

Micreos Group is headquartered in Bilthoven, Netherlands, in the Europe region.

Who are Micreos Group's main competitors?

Emerging players on record are SkinBioTherapeutics, Eligo Bioscience, Locus Fermentation Solutions and AOBiome. Broad incumbents are BioGaia, International Flavors & Fragrances (IFF), Novonesis (formerly Novozymes / Chr. Hansen) and DuPont Nutrition & Biosciences (IFF Danisco). Direct peers are Intralytix and Phagelux.

Does Micreos Group have an API?

No public API is recorded for Micreos Group.

What industry is Micreos Group in?

Micreos Group's product category is Antimicrobial Biotechnology. Its primary akta.pro industry code is AFAJAFAF, Natural Antimicrobials & Clean-Label Preservatives (Plant Extracts, Essential Oils, Fermented Extracts), with a secondary code of AFAJAJAF, Protective Cultures & Biopreservation (Anti-Listeria, Anti-Mold, Shelf-Life Cultures). Its NAICS code is 325412 and its SIC code is 2000.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
FinSMEsMicreos Raises €32M in FundingMicreos, a biotechnology company based in The Hague, secured €32 million in funding to accelerate its clinical development programs for conditions like atopic dermatitis and MRSA wounds. The funding will support the advancement of its lead compounds, XZ.700 and SP.800, which target specific bacteria while preserving beneficial strains. This capital injection is part of Micreos's strategy to replace antibiotics with its proprietary endolysin technology.PR NewswireEuGH ebnet Weg für Einsatz von Phagen gegen ListerienThe European Court of Justice issued a ruling allowing food manufacturers to use bacteriophages against Listeria bacteria, addressing a regulatory gap in European food safety law without a specific EU framework. Listeria outbreaks across Spain, Germany, Austria, Switzerland, and the Netherlands caused hundreds of illnesses and deaths, highlighting the inadequacy of current safety measures. The Dutch biotech company Micreos Food Safety's product Listex, already approved as safe by the FDA in 2016, can now be used in Europe, with MEPs calling on the European Commission to develop specific EU phage regulations.PR NewswireFDA Approves PhageGuard-E as New Food Processing Aid Against E. Coli O157FDA and USDA have approved PhageGuard-E as a Generally Recognized as Safe (GRAS) food processing aid against E. coli O157, developed by Dutch biotechnology company Micreos. The product uses natural bacteriophages as an alternative to chemical interventions and is targeted at the US beef industry to reduce contamination on beef carcasses, primals, and trimmings. Industrial scale projects with US meat processing companies are set to begin shortly, with research from the University of Nevada demonstrating superior efficacy compared to current chemical treatments.PR NewswireAntibiotic Alternative Micreos wins Most Impactful InnovationMicreos was selected as the most impactful innovation in The Netherlands for its antibiotic alternative technology, a decision made by a professional jury at the Making Waves conference. The company will represent the country at the semi-finals of Ideas from Europe in Tallinn, Estonia. This recognition highlights the potential of Micreos' endolysin technology to address global antibiotic resistance.